Replies to post #2877 on Synaptogenix Inc (SNPX)

[F1ash]

I have tried, unsuccessfully for the most part. Unfortunately, often having money at stake removes all objectivity. Anyone who points out inconsistencies or ridiculous statements like "Our unblinded, non-placebo controlled, underpowered, two year long dose optimization study was designed to fail quickly" is just trying to "steal shares" apparently.

The most egregious sin imho is the fact that they are presenting charts labeled "all patients" for a time period that covers a trial that started with 32 patient's and ended with 25. If "all patients means 32 then they somehow "filled in" the missing data for the dropouts. They should declare what method they used.

If they mean 25 when saying "all patients", that is very very misleading. IR ignored my request for clarification. Disconcerting!!!

[InTheTrenches]

"My biggest concern is nobody is looking at or touching this."

Biotwitter "thought leaders" (Adam F/Alfredo F, etc) are only giving it a cursory look or aren't even reviewing it, so most of their "sheep" aren't digging much deeper. And I don't know of anyone else with a following on twitter (other than @KSSMDPhd) who gives it >50% chance of succeeding.

Unfortunately, Bryostatin Phase 2a (single dose, safe, PK/PD positive) doesn't give much readthrough to Phase 2b (7 doses across 12-weeks, double-blind placebo controlled) SIB results.

So we have to rely on the extensive preclinical mouse/mammal models published by Dr. Alkon, upbeat scientific presentations at conferences by Wilke/Alkon, and 3 compassionate-use patients.

It's either the buy of the 21st century or just another startup biotech. I believe we'll see positive results, but there's a lot of extrapolation in my belief. There's no certainty to results being positive, but the deeper one digs, the more intriguing this binary event looks.

[donsker]

I thinks that's because it hasn't been on the public's radar until only recently. Many don't want to take the time to DD & are giving it a pass. Less likely for a bear attack through AF, et al. Let them call it a "lottery" and move on. But I think that many of us who (& I'm late to this) like the prospects are getting the word out, slowly but surely.